TLR2

Across TCGA pan-cancer cohorts, TLR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TLR2 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TLR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLR2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, DLBC, and CESC are the cancer types where TLR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
CESC	OS	Median	III,IV	0.068	0.756	<.001	12	view →
PRAD	DFS	Median	All	0.160	0.886	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.859	0.436	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TLR2–OV (OS)

Open the OV breakdown →